Your browser doesn't support javascript.
loading
Hypoglycaemia and its management in primary care setting.
Ibrahim, Mahmoud; Baker, Jason; Cahn, Avivit; Eckel, Robert H; El Sayed, Nuha Ali; Fischl, Amy Hess; Gaede, Peter; Leslie, R David; Pieralice, Silvia; Tuccinardi, Dario; Pozzilli, Paolo; Richelsen, Bjørn; Roitman, Eytan; Standl, Eberhard; Toledano, Yoel; Tuomilehto, Jaakko; Weber, Sandra L; Umpierrez, Guillermo E.
Affiliation
  • Ibrahim M; EDC Center for Diabetes Education, McDonough, Georgia, USA.
  • Baker J; Weill Cornell Medicine, New York, New York, USA.
  • Cahn A; The Diabetes Unit & Endocrinology and Metabolism Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • Eckel RH; University of Colorado Denver Anschutz Medical Campus and University of Colorado Hospital, Denver, Colorado, USA.
  • El Sayed NA; Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Fischl AH; University of Chicago Kovler Diabetes Center, Chicago, Illinois, USA.
  • Gaede P; Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark.
  • Leslie RD; Blizard Institute, Queen Mary, University of London, London, UK.
  • Pieralice S; Centre of Immunobiology, Barts and the London School of Medicine, Queen Mary, University of London, London, UK.
  • Tuccinardi D; Unit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
  • Pozzilli P; Unit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
  • Richelsen B; Centre of Immunobiology, Barts and the London School of Medicine, Queen Mary, University of London, London, UK.
  • Roitman E; Unit of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy.
  • Standl E; Steno Diabetes Center Aarhus and Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
  • Toledano Y; Institute of Diabetes, Technology and Research, Clalit Health Services, Herzelia, Israel.
  • Tuomilehto J; Forschergruppe Diabetes eV at Munich Helmholtz Centre, Munich, Germany.
  • Weber SL; Division of Maternal Fetal Medicine, Helen Schneider Women's Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Umpierrez GE; University of Helsinki, Helsinki, Finland.
Diabetes Metab Res Rev ; 36(8): e3332, 2020 11.
Article in En | MEDLINE | ID: mdl-32343474
ABSTRACT
Hypoglycaemia is common in patients with type 1 diabetes and type 2 diabetes and constitutes a major limiting factor in achieving glycaemic control among people with diabetes. While hypoglycaemia is defined as a blood glucose level under 70 mg/dL (3.9 mmol/L), symptoms may occur at higher blood glucose levels in individuals with poor glycaemic control. Severe hypoglycaemia is defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions to assure neurologic recovery. Hypoglycaemia is the most important safety outcome in clinical studies of glucose lowering agents. The American Diabetes Association Standards of Medical Care recommends that a management protocol for hypoglycaemia should be designed and implemented by every hospital, along with a clear prevention and treatment plan. A tailored approach, using clinical and pathophysiologic disease stratification, can help individualize glycaemic goals and promote new therapies to improve quality of life of patients. Data from recent large clinical trials reported low risk of hypoglycaemic events with the use of newer anti-diabetic drugs. Increased hypoglycaemia risk is observed with the use of insulin and/or sulphonylureas. Vulnerable patients with T2D at dual risk of severe hypoglycaemia and cardiovascular outcomes show features of "frailty." Many of such patients may be better treated by the use of GLP-1 receptor agonists or SGLT2 inhibitors rather than insulin. Continuous glucose monitoring (CGM) should be considered for all individuals with increased risk for hypoglycaemia, impaired hypoglycaemia awareness, frequent nocturnal hypoglycaemia and with history of severe hypoglycaemia. Patients with impaired awareness of hypoglycaemia benefit from real-time CGM. The diabetes educator is an invaluable resource and can devote the time needed to thoroughly educate the individual to reduce the risk of hypoglycaemia and integrate the information within the entire construct of diabetes self-management. Conversations about hypoglycaemia facilitated by a healthcare professional may reduce the burden and fear of hypoglycaemia among patients with diabetes and their family members. Optimizing insulin doses and carbohydrate intake, in addition to a short warm up before or after the physical activity sessions may help avoiding hypoglycaemia. Several therapeutic considerations are important to reduce hypoglycaemia risk during pregnancy including administration of rapid-acting insulin analogues rather than human insulin, pre-conception initiation of insulin analogues, and immediate postpartum insulin dose reduction.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Primary Health Care / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Hypoglycemia / Hypoglycemic Agents Type of study: Guideline Limits: Humans Language: En Journal: Diabetes Metab Res Rev Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Primary Health Care / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Hypoglycemia / Hypoglycemic Agents Type of study: Guideline Limits: Humans Language: En Journal: Diabetes Metab Res Rev Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2020 Type: Article Affiliation country: United States